2006 Annual Meeting | Management of Common Behavioral Disturbances in Dementia

Date Sunday 04/02/06

Time 06:00 PM - 09:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Dinner Seminar

Director(s) Kimford J. Meador, MD, FAAN

Topic(s) Cognitive Neurology/Neurologic Disorders Presenting with Psychiatric Symptoms

Learning Objectives Upon Completion:
Participants should gain knowledge of the behavioral and pharmacological management of behavioral disturbances in patients with dementia.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Resident, Nurse

Event Timeline
06:00 PM - 06:10 PM		Introduction Kimford J. Meador, MD, FAAN
06:00 PM - 09:00 PM		Dinner
06:10 PM - 07:05 PM		Behavioral Effects of Anti-dementia Agents Jeffrey L. Cummings, MD, FAAN
07:05 PM - 08:00 PM		Role of Psychotropics in Treatment of Behavioral Disorders in Dementia Daniel Kaufer, MD, FAAN
08:00 PM - 08:40 PM		Case Studies Kimford J. Meador, MD, FAAN
08:40 PM - 09:00 PM		Questions and Case Studies From Audience

Faculty Disclosures
Kimford J. Meador, MD, FAAN	The institution of Dr. Meador has received research support from NIH. The institution of Dr. Meador has received research support from Eisai. The institution of Dr. Meador has received research support from Medtronics. The institution of Dr. Meador has received research support from The Epilepsy Consortium.
Jeffrey L. Cummings, MD, FAAN	Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
Daniel Kaufer, MD, FAAN	No disclosure on file

��ɫ��

��ɫ��